Also known as: CC
Colorectal cancer is cancer that begins in the colon or rectum. It is one of the most common gastrointestinal cancers and a major cause of cancer burden worldwide.
At ESMO GI 2026, experts presented the EBAI framework classifying AI-based biomarkers into three validation tiers. Clinical data showed AI detecting MSI with 96-98% sensitivity and MRI-guided brachytherapy improving recurrence-free survival.
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Two studies link delayed colorectal cancer treatment to worse outcomes. A JAMA Oncology study of 112,672 patients found delays over six weeks hurt survival. High socioecological burden also delays care.
A major clinical trial found that Grail's Galleri blood test did not reduce late-stage cancer diagnoses, raising questions about multi-cancer early detection. Meanwhile, the FDA approved a second blood-based colorectal cancer screening test, and an AI-powered liquid biopsy showed promise for Ewing sarcoma.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Colorectal Cancer Alliance tackles rising young-onset cases with Never Too Young Taskforce and Project Cure CRC; LEAD FROM BEHIND wins Webby Award. Screening changes make 20M more eligible.
A study finds end-to-side anastomosis for Crohn’s disease may reduce endoscopic recurrence, while global data show early-onset colorectal cancer has the highest GI cancer burden in young adults, with rising incidence. Both studies highlight evolving challenges and treatment options in gastroenterology.
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
At ESMO GI 2026, the GALAXY study showed ctDNA tests can identify colorectal cancer patients who benefit from adjuvant chemotherapy. A separate study found CLK3 regulates colorectal tumor angiogenesis by stabilizing HIF1α.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07781852 |
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07781774 |
Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach |
NOT_YET_RECRUITING | NA |
| NCT07781306 |
PrOspEctive Metastases Imaging (POEM) |
RECRUITING | |
| NCT07778628 |
WT1 in Colorectal Adenocarcinoma |
COMPLETED | |
| NCT07775859 |
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers |
NOT_YET_RECRUITING | |
| NCT07775287 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07768358 |
Tucatinib Continuation Study |
NOT_YET_RECRUITING | PHASE4 |
| NCT07766044 |
A One-year Follow-up of Incisional Hernia Formation Between Device Assisted and Manual Laparotomy Closure |
RECRUITING | NA |
| NCT07759921 |
Novel Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer |
RECRUITING | NA |
| NCT07752875 |
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
